Irinotecan for children with relapsed solid tumors

Toshiji Shitara; Akira Shimada; Ryoji Hanada; Tadashi Matsunaga; Keisei Kawa; Hideo Mugishima; Tohru Sugimoto; Jun Ichi Mimaya; Atsushi Manabe; Masahito Tsurusawa; Yoshiaki Tsuchida

doi:10.1080/08880010500457152

Irinotecan for children with relapsed solid tumors

Toshiji Shitara, Akira Shimada, Ryoji Hanada, Tadashi Matsunaga, Keisei Kawa, Hideo Mugishima, Tohru Sugimoto, Jun Ichi Mimaya, Atsushi Manabe, Masahito Tsurusawa, Yoshiaki Tsuchida

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m ²/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

Original language	English
Pages (from-to)	103-110
Number of pages	8
Journal	Pediatric Hematology and Oncology
Volume	23
Issue number	2
DOIs	https://doi.org/10.1080/08880010500457152
Publication status	Published - Mar 2006
Externally published	Yes

Keywords

Clinical trials
Irinotecan
Nephroblastoma
Neuroblastoma
Rhabdomyosarcoma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1080/08880010500457152

Cite this

@article{44dfd769c62045a186a9bd3e4951ba38,

title = "Irinotecan for children with relapsed solid tumors",

abstract = "Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.",

keywords = "Clinical trials, Irinotecan, Nephroblastoma, Neuroblastoma, Rhabdomyosarcoma",

author = "Toshiji Shitara and Akira Shimada and Ryoji Hanada and Tadashi Matsunaga and Keisei Kawa and Hideo Mugishima and Tohru Sugimoto and Mimaya, {Jun Ichi} and Atsushi Manabe and Masahito Tsurusawa and Yoshiaki Tsuchida",

note = "Funding Information: The authors are deeply grateful to Cynthia Yenches for editorial assistance and to K. Asami, B. Higuchi, A. Kawaguchi, and T. Hori for their contributions to the study. This work was supported by a Grant-in-Aid for Cancer Research (No. 9-14) from the Ministry of Health, Labour and Welfare of the Government of Japan.",

year = "2006",

month = mar,

doi = "10.1080/08880010500457152",

language = "English",

volume = "23",

pages = "103--110",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Irinotecan for children with relapsed solid tumors

AU - Shitara, Toshiji

AU - Shimada, Akira

AU - Hanada, Ryoji

AU - Matsunaga, Tadashi

AU - Kawa, Keisei

AU - Mugishima, Hideo

AU - Sugimoto, Tohru

AU - Mimaya, Jun Ichi

AU - Manabe, Atsushi

AU - Tsurusawa, Masahito

AU - Tsuchida, Yoshiaki

N1 - Funding Information: The authors are deeply grateful to Cynthia Yenches for editorial assistance and to K. Asami, B. Higuchi, A. Kawaguchi, and T. Hori for their contributions to the study. This work was supported by a Grant-in-Aid for Cancer Research (No. 9-14) from the Ministry of Health, Labour and Welfare of the Government of Japan.

PY - 2006/3

Y1 - 2006/3

N2 - Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

AB - Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m 2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

KW - Clinical trials

KW - Irinotecan

KW - Nephroblastoma

KW - Neuroblastoma

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=31644434536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31644434536&partnerID=8YFLogxK

U2 - 10.1080/08880010500457152

DO - 10.1080/08880010500457152

M3 - Article

C2 - 16651238

AN - SCOPUS:31644434536

SN - 0888-0018

VL - 23

SP - 103

EP - 110

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

IS - 2

ER -

Irinotecan for children with relapsed solid tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this